← Back to Clinical Trials
Recruiting NCT06464744

NCT06464744 Efficacy of rTMS Treatment After Spinal Cord Injury

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06464744
Status Recruiting
Phase
Sponsor Oslo University Hospital
Condition Spinal Cord Injuries
Study Type INTERVENTIONAL
Enrollment 20 participants
Start Date 2024-01-15
Primary Completion 2028-09

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 80 Years
Study Type INTERVENTIONAL
Interventions
Repetitive transcranial magnetic stimulation (rTMS)Placebo stimulation using a placebo coil

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 20 participants in total. It began in 2024-01-15 with a primary completion date of 2028-09.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

There is accumulating evidence that neuromodulation by repetitive transcranial magnetic stimulation (rTMS) of the motor cortex holds promise as a treatment for rehabilitation of motor function following a spinal cord injury. This study is designed to assess the clinical potential of non-invasive stimulation of the primary motor cortex to improve motor functions.The results will help to evaluate the clinical relevance of motor cortex stimulation for motor functions in patients with spinal cord injury. The outcomes of this study could potentially support the initiation of a larger clinical trial and the development of a new routine treatment.

Eligibility Criteria

Inclusion Criteria: * Age over 18 years and less than 80 years * Chronic patients with an incomplete cervical and/or thoracic spinal cord injury (traumatic and non-traumatic) affecting upper and/or lower extremities (i.e., C4-T12 and classified as ASIA C or D) (Figure 138). * Capable and willing to provide informed consent and able to adhere to the treatment schedule * Patients who can be followed for the whole duration of the study 6.3 Exclusion criteria * Contraindication to rTMS: * past severe head trauma * history of epilepsy or ongoing epilepsy * active cerebral tumor * intracranial hypertension * implanted ferromagnetic devices such as cardiac pacemaker and neurostimulator and cochlear implants * pregnancy or lactation. * Any clinically significant or unstable medical or psychiatric disorder * Other ongoing research protocol or recent past protocol within two months before the inclusion * History of treatment with Deep Brain Stimulation (DBS) * Subjects protected by law (guardianship or tutelage measure) * History of substance abuse (alcohol, drugs) * Pending litigation * Impossibility to understand the protocol or to fill out the forms * Chronic use of sedative medication * Participation in another clinical trial evaluating spinal cord injury

Contact & Investigator

Central Contact

Mark Züchner, MD, PhD

✉ mark.zuchner@medisin.uio.no

📞 +47 23070000

Principal Investigator

Bjørn Atle Bjørnbeth, MD,PhD

STUDY CHAIR

Oslo University Hospital

Frequently Asked Questions

Who can join the NCT06464744 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Spinal Cord Injuries. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06464744 currently recruiting?

Yes, NCT06464744 is actively recruiting participants. Contact the research team at mark.zuchner@medisin.uio.no for enrollment information.

Where is the NCT06464744 trial being conducted?

This trial is being conducted at Oslo, Norway.

Who is sponsoring the NCT06464744 clinical trial?

NCT06464744 is sponsored by Oslo University Hospital. The principal investigator is Bjørn Atle Bjørnbeth, MD,PhD at Oslo University Hospital. The trial plans to enroll 20 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology